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Induction of T Lymphocytes Specific for Bovine Viral Diarrhea Virus in
Calves with Maternal Antibody
Abstract
Passive antibody to bovine viral diarrhea virus (BVDV) acquired through colostrum intake may interfere with
the development of a protective immune response by calves to this virus. The objective of this study was to
determine if calves, with a high level of maternal antibody to bovine viral diarrhea virus (BVDV), develop
CD4+, CD8+, or γδ T lymphocyte responses to BVDV in the absence of a measurable humoral immune
response. Colostrum or milk replacer fed calves were challenged with virulent BVDV at 2-5 weeks of age and/
or after maternal antibody had waned. Calves exposed to BVDV while passive antibody levels were high did
not mount a measurable humoral immune response to BVDV. However, compared to nonexposed animals,
these animals had CD4+, CD8+, and γδ T lymphocytes that were activated by BVDV after exposure to in vitro
BVDV. The production of IFNγ by lymphocytes after in vitro BVDV exposure was also much greater in
lymphocytes from calves exposed to BVDV in the presence of maternal antibody compared to the
nonexposed calves. These data indicate that calves exposed to BVDV while maternal antibody levels are high
can develop antigen specific CD4+, CD8+, and γδ T lymphocytes in the absence of an active antibody
response. A manuscript presented separately demonstrates that the calves with T lymphocytes specific for
BVDV in this study were also protected from virulent BVDV genotype 2 challenge after maternal antibody
became undetectable.
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Diarrhea Virus in Calves with Maternal Antibody
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ABSTRACT
Passive antibody to bovine viral diarrhea virus (BVDV) acquired through colostrum intake
may interfere with the development of a protective immune response by calves to this virus.
The objective of this study was to determine if calves, with a high level of maternal antibody
to bovine viral diarrhea virus (BVDV), develop CD41, CD81, or gd T lymphocyte responses
to BVDV in the absence of a measurable humoral immune response. Colostrum or milk re-
placer fed calves were challenged with virulent BVDV at 2–5 weeks of age and/or after ma-
ternal antibody had waned. Calves exposed to BVDV while passive antibody levels were high
did not mount a measurable humoral immune response to BVDV. However, compared to
nonexposed animals, these animals had CD41, CD81, and gd T lymphocytes that were ac-
tivated by BVDV after exposure to in vitro BVDV. The production of IFNg by lymphocytes
after in vitro BVDV exposure was also much greater in lymphocytes from calves exposed to
BVDV in the presence of maternal antibody compared to the nonexposed calves. These data
indicate that calves exposed to BVDV while maternal antibody levels are high can develop
antigen specific CD41, CD81, and gd T lymphocytes in the absence of an active antibody
response. A manuscript presented separately demonstrates that the calves with T lympho-
cytes specific for BVDV in this study were also protected from virulent BVDV genotype 2
challenge after maternal antibody became undetectable.
INTRODUCTION
BOVINE VIRAL DIARRHEA VIRUS (BVDV) is a pestivirus responsible for major economic losses to the cat-tle industry due to respiratory, enteric, and reproductive disease (22). The disease manifestation varies
with biotype, genotype, and strain of the BVD virus. BVDV isolates are designated as either cytopathic or
noncytopathic based on the ability to cause cytolysis in cell culture (20). Both biotypes of BVDV can cross
the placenta leading to abortion, mummification, or congenital defects (1). Fetal infection with the noncy-
topathic strains may lead to immunotolerant persistently infected animals (37), the most common source of
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transmission within a herd (22). Superinfection of a persistently infected animal with a homologous cyto-
pathic strain may cause a fatal mucosal disease (5,11).
Two genotypes of BVDV have also been designated based on genomic differences in the 59 untranslated
region and differences in the monoclonal antibody binding pattern (30,33). Disease caused by genotype 1
BVDV (BVDV1) infection in immunocompetent animals is usually mild and transient, while disease caused
by genotype 2 BVDV (BVDV2) can be severe and frequently fatal (13,14,32). Young calves are protected
from clinical signs due to either genotype by passively acquired antibody derived from colostrum (6,23).
Maternally derived antibody to BVDV has a half life of approximately 3 weeks and is usually catabolized
by approximately 6 months of age (10,15,26,28). High titers of maternal antibody are capable of prevent-
ing the induction of an active antibody response to vaccination in calves (10). This has led to the conclu-
sion that it is necessary to wait until maternal antibody has waned to effectively induce protective immu-
nity.
Stimulating an immune response to BVDV in the presence of maternal antibody could generate a pro-
tective memory response to this virus at a much earlier age. Cell-mediated immune responses to some
pathogens of domestic animals can occur in the presence of maternal antibody and in the absence of a de-
tectable humoral response (18,27,38). Protective immune responses mediated by T lymphocytes may be
overlooked because there is no simple serology based test to detect them. The objective of this trial was to
determine if calves with a high level of maternal antibody to BVDV develop CD41, CD81, or gd T lym-
phocyte responses to BVDV in the absence of a humoral immune response.
MATERIALS AND METHODS
Experimental design. Eighteen mixed breed male and female calves were used to determine if BVDV-
specific T lymphocytes were generated when calves with circulating maternal antibody are challenged with
BVDV. Pooled colostrum from cows immunized against BVDV during pregnancy, or milk replacer, was
fed to BVDV-seronegative calves within 48 h of birth as described (34). The titer of neutralizing antibody
against BVDV1 and BVDV2 in the colostrum and first milk was determined as previously described (8).
The neutralizing antibody titer of the pooled colostrum to BVDV1b-NY-1 was 1/128,000 and titer to
BVDV2-1373 was 1/4,096,000. The corresponding titers in the second milking after parturition were 1/1,448
against BVDV1 and 1/6,848 against BVDV2.
Calves receiving colostrum or milk replacer were assigned to one of four treatments. Groups A and B
(n 5 6 in each group) received colostrum with a high titer of antibody against BVDV, and groups C and
D (n 5 3 in each group) were fed milk replacer. Animals from groups A and C were inoculated intranasally
with 5 mL (2.5 mL in each nostril) of freeze/thaw lysate from cultured bovine cells infected with BVDV2-
1373 at 2–5 weeks of age. The titer of the lysates used for the inoculum was 106 TCID50/mL. The inocu-
lated animals were housed separately from the non-inoculated animals for the remainder of the trial. Groups
B and D were not challenged with BVDV at 2–5 weeks of age. Following inoculation, all surviving groups
of animals were sampled approximately monthly for antibodies to BVDV, T lymphocyte subset activation
by in vitro BVDV, and production of IFNg by lymphocytes after in vitro exposure. Antibodies of mater-
nal origin were monitored as described (34) until they were no longer detectable in the serum of calves in
all treatment groups. At this time, all groups of animals were challenged with BVDV2-1373 as described
above to determine if they had protective immunity.
Viral stocks of BVDV2-1373, BVDV2-890, BVDV1b-NY-1, and BVDV1b-TGAN were propagated as
described previously (33). BVDV1-970 virus was grown in bovine turbinate (BT) cells in McCoys 5A
medium supplemented with 10% fetal bovine serum that was free of BVDV virus and antibodies. Flasks
of BT cells were seeded for 24 h and infected with 106 TCID50 of BVDV. Virus was grown for 48 h and
frozen at 280°C. Culture flasks were then thawed and cell culture media centrifuged at 2,0003 g to re-
move cellular debris. Viral titers of BVDV were determined as described previously (7).
Measurement of T cell activation. Antigen-specific T cell subset activation was detected using a mod-
ification of a previously described procedure (31). Animals in all treatment groups were sampled for in
vitro T cell responsiveness approximately monthly from 2 to 32 weeks following challenge with BVDV at
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2–5 weeks of age. Peripheral blood mononuclear cells (PBMC) were isolated from approximately 40 mL
of citrated blood, washed twice in Hanks balanced salt solution (HBSS), and resuspended at 4 3 105 cells
in 200 mL of RPMI media containing 2 mM L-glutamine, penicillin (60 mg/mL), 20 mM HEPES, and 7.5%
fetal bovine serum (cRPMI). Triplicate wells of PBMCs from all animals were inoculated with a mock con-
trol of 25 mL of cRPMI or 25 mL of cRPMI containing BVDV2-890 (TCID50 106/mL), BVDV2-1373
(TCID50 4 3 106/mL), BVDV1-970 (TCID50 107/mL), BVDV1b-TGAN (TCID50 4 3 106/mL), or Con-
canavalin A for 5 days at 39°C in a 5% CO2 atmosphere. The amount of viral antigen used in the CD25
expression assay was based on levels that gave an optimal response in animals previously vaccinated with
modified live BVDV vaccine containing BVDV1.
Following the 5 days of culture, cells were washed twice with Hanks balanced salt solution (HBSS) and
twice with a phosphate buffered saline (PBS) solution containing 0.5% bovine serum albumin and 0.1%
NaN3 (PBS11). The washed cells were then stained with murine monoclonal antibodies (VMRD, Pullman,
WA) specific for bovine CD4 (CACT138A), CD8 (CACT80C), and gd (GB21A) T cells and for bovine
CD25 (CACT108A). The antibodies specific for CD4, CD8, and a matched isotype control were of the
IgG1 isotype. Antibodies specific for gd TCR and a matched isotype control were of the IgG2b isotype.
The antibody specific for CD25 was of the IgG2a isotype. Following a 30-min incubation at 4°C, cells were
washed four times with PBS11 and then stained with phycoerythrin labeled anti-murine IgG2a and fluo-
rescein isothiocyanate labeled anti-murine IgG2b (gd and isotype control) or anti-IgG1 (CD4, CD8, and
isotype control) (Caltag, Burlingame, CA). After 30 min at 4°C, cells were washed five times in HBSS
without phenol red and fixed in 1% paraformaldehyde. Triplicate wells were pooled prior to counting.
Measurement of in vitro IFNg production. Supernatants were collected from PBMC cultured with and
without BVDV2-890 after 5 days of incubation and frozen at 220°C prior to analysis. Upon thawing, su-
pernatant was pooled from six equivalent wells of a 96-well plate per sample. The Bovigam ELISA kit
(Biocor Animal Health, Omaha, NE) was used to measure IFN-g levels in the supernatants. The ELISA
was performed according to the protocol supplied by the manufacturer, except that each sample was tested
in triplicate rather than duplicate and the volume of sample per well was decreased from 50 to 25 mL so
that optical density in most positive samples would not exceed the microplate reader’s photometric range.
A standard curve for protein concentration was derived by regression of four ten-fold dilutions of recom-
binant bovine IFN-g (Novartis Animal Health, Basel, Switzerland). Optical density readings at a wave-
length of 450 nm were obtained with a Vmax Microplate Reader (Molecular Devices, Sunnyvale, CA).
Data analysis. Antigen-specific T cell responsiveness to in vitro antigen was determined by analyzing a
total of 5,000 cells using a flow cytometer (Becton Dickinson FACScan, San Jose, CA). Data are reported
as a CD25 expression index, which is a ratio of the lymphocyte responsiveness from each animal when
stimulated with antigen versus when not stimulated with antigen. The Expression Index was ([calculated as
follows: % stimulated T cells positive for CD25] * [mean fluorescent intensity of stimulated T cells posi-
tive for CD25])/([% unstimulated T cells positive for CD25] * [mean fluorescent intensity of unstimulated
T cells positive for CD25]). Data are reported as treatment means plus the standard error of the mean. For
clarity of presentation, the expression indices and IFNg data are pooled by 10-week intervals following the
first challenge with BVDV. A Wilcoxon rank sum test was used to determine the level of significance of
the differences in CD25 expression indices and IFNg production between treatment groups.
RESULTS
Calves fed colostrum with high titers of BVDV antibody did not show clinical signs of disease from
BVDV after challenge at 2–5 weeks of age (34). The calves in group C that were fed milk replacer and
challenged with BVDV at 2–5 weeks of age became acutely ill with BVDV and had to be euthanized.
Colostrum fed calves had average serum neutralizing antibody titers of 2,211 against BVDV1 and 11,456
against BVDV2 at 1 week of age (34). Antibodies to BVDV1 and BVDV2 from colostrum fed calves de-
clined at similar rates for the calves exposed to BVDV at 2–5 weeks of age compared to the nonexposed
calves (34). The calves in groups A, B, and D were sampled for T lymphocyte subset responsiveness to
four strains of BVDV in vitro, approximately monthly, until maternal antibodies were no longer detectable
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(between 7 and 9 months of age). Peripheral blood CD41, CD81, and gd T cells from animals in all sur-
viving treatment groups responded to in vitro stimulation with Concanavalin A (ConA) by increasing ex-
pression of CD25, indicating that all T cell subsets were capable of responding. Following exposure to
ConA the average CD25 Expression Indices for CD41, CD81, and gd T cells of calves challenged with
BVDV at 2–5 weeks of age in the presence of colostral antibody were 42.8, 33.1, and 54.1, respectively.
The average CD25 Expression Indices of CD41, CD81, and gd T cells in response to ConA by calves that
were not challenged with BVDV at 2–5 weeks of age in the presence of colostral antibody were 50.2, 41.5,
and 36.2, respectively.
Antigen-specific CD41, CD81, and gd T cell activation, in response to both BVDV1 and BVDV2 in
vitro, was detected in calves challenged with BVDV2 while they had high titers of maternal antibody. Vari-
ation in the response of the three subsets of lymphocytes to the four strains of BVDV was observed (Figs.
1–4). The T lymphocyte responses of the calves fed milk replacer and not exposed to BVDV (group D)
were not significantly (p , 0.05) different from the T lymphocyte responses of the calves fed colostrum
and not exposed to BVDV (group B) (data not shown). Production of IFNg by PBMC exposed in vitro to
BVDV2 (strain 890) was significantly greater for calves exposed to BVDV at 2–5 weeks of age compared
to colostrum fed calves that were not exposed to BVDV at 2–5 weeks of age (Fig. 5). Calves from all sur-
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FIG. 1. CD25 Expression Index (mean6 SEM) for T cell subsets stimulated in vitro with BVDV2-1373 from
calves fed colostrum and not challenged with BVDV (group B) and calves fed colostrum and challenged with BVDV2-
1373 at 2–5 weeks of age (group A). Data is presented as weeks after challenge with BVDV at 2–5 weeks of age and
is pooled from weeks 2–10 (n 5 33), 11–20 (n 5 37), and 21–32 (n 5 31). There were no significant differences be-
tween treatment groups.
viving treatment groups were challenged with BVDV2-1373 when maternal antibodies were no longer de-
tectable in peripheral blood. The calves in group A that had previously been exposed to BVDV when ma-
ternal antibody levels were high were protected from challenge compared to the animals from groups B and
D that had not been previously exposed (34).
DISCUSSION
Previously, we reported that a protective immune response can be mounted by calves exposed to viru-
lent BVDV in the face of passive antibody (34). In this report, we characterize the nature of that response.
This is the first report to demonstrate that calves challenged with BVDV while maternal antibody levels
are high can develop BVDV-specific T lymphocyte subset responses to in vitro BVDV antigen. The T lym-
phocyte response occurred in the absence of a detectable humoral immune response to BVDV in the chal-
lenged calves. As reported elsewhere (34), calves challenged with BVDV2-1373 after ingestion of colostrum
with high titers of BVDV antibody did not develop a detectable serum neutralizing antibody response to
BVDV1 or BVDV2. The amount of serum neutralizing antibody to BVDV declined steadily following
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FIG. 2. CD25 Expression Index (mean6 SEM) for T cell subsets stimulated in vitro with BVDV2-890 from calves
fed colostrum and not challenged with BVDV (group B) and calves fed colostrum and challenged with BVDV2-1373
at 2–5 weeks of age (group A). Data is presented as weeks after challenge with BVDV at 2–5 weeks of age and is
pooled from weeks 2–10 (n 5 33), 11–20 (n 5 37), and 21–32 (n 5 31). *p , 0.05, **p , 0.01, level of statistical sig-
nificance between exposed and nonexposed values (mean6 SEM).
colostrum ingestion, indicating the antibodies were of maternal origin. In a similar experiment, calves chal-
lenged with BVDV while maternal antibody circulated were able to mount a moderate IgG2 response spe-
cific for BVDV (23). As discussed by Howard and colleagues, the level of serum neutralizing antibodies
to BVDV in the calves mounting the IgG2 response did not decline at the expected rate for catabolism of
maternally derived antibodies (23). The IgG2 response and prolonged serum neutralizing antibody titer in
that trial may indicate that maternal antibody levels were not adequate to completely block a humoral re-
sponse.
In the current trial, individual T cell subsets from colostrum fed, BVDV challenged calves were all ac-
tivated to some degree in response to the homologous BVDV genotype. The T lymphocyte response by the
animals exposed to BVDV while maternal antibody circulated persisted several months after exposure, in-
dicating that a strong CMI response had occurred. When combined with surface phenotype markers, de-
tection of CD25 expression indicates activation by individual T lymphocyte populations in response to spe-
cific antigen. The level of activation, however, does not provide information regarding the function of the
responding T cells (29,31). The CD41 and CD81 T cells activated by BVDV are expected to produce cy-
tokines and induce cytotoxic effects on infected cells, respectively. Purified CD41 T cells from BVDV ex-
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FIG. 3. CD25 Expression Index (mean6 SEM) for T cell subsets stimulated in vitro with BVDV1-970 from calves
fed colostrum and not challenged with BVDV (group B) and calves fed colostrum and challenged with BVDV2-1373
at 2–5 weeks of age (group A). Data is presented as weeks after challenge with BVDV at 2–5 weeks of age and is
pooled from weeks 2–10 (n 5 33), 11–20 (n 5 37), and 21–32 (n 5 31). *p , 0.05, level of statistical significance be-
tween exposed and nonexposed values (mean6 SEM).
posed animals produce a predominant IL-4 cytokine response upon in vitro exposure to BVDV infected
monocytes and CD81 T cells produce a predominant IFN and IL-2 response (35). Cytotoxic T lymphocytes
(CTL) capable of MHC restricted killing of BVDV infected targets can be isolated from peripheral blood
of animals immune to BVDV (3). The precise role of gd T cells in cattle and other species is not well de-
fined, making it difficult to explain the biological significance of antigen-specific gd T cells following vac-
cination. Gamma delta T cells have been shown to act as antigen-presenting cells and cytotoxic T lym-
phocytes in cattle and as helper T cells in mice (4,12). In the current trial, gd T cells were activated by both
genotypes of BVDV in vitro. This result may reflect the less specific nature of the gd T cell population in
response to antigen (25) or the detection of epitopes conserved in both genotypes.
In the current trial, PBMC from calves exposed to BVDV while maternal antibody levels were high pro-
duced greater amounts of IFNg than nonexposed counterparts upon re-stimulation with BVDV antigens.
The relative contribution of individual T cell subsets to IFNg production in the mixed lymphocyte pool was
not determined. BVDV-specific production of IFNg has been demonstrated in PBMC and isolated CD41
and CD81 populations from animals exposed to BVDV antigens (35,39). Isolated CD41 and CD81 T cells
from immune animals proliferate in response to BVDV-infected monocytes and the primary source of IFNg
in supernatants from the proliferating T cells appears to be the CD81 T cells. Production of IFNg by bovine
gd T cells in response to BVDV has not been reported previously, although IFNg production by bovine gd
T cells in response to specific antigen has been demonstrated in a Theileria parva study (16).
T LYMPHOCYTES SPECIFIC FOR BVDV
19
FIG. 4. CD25 Expression Index (mean 6 SEM) for T cell subsets stimulated in vitro with from calves fed colostrum
and not challenged with BVDV (group B) and calves fed colostrum and challenged with BVDV2-1373 at 2–5 weeks
of age (group A). Data is presented as weeks after challenge with BVDV at 2–5 weeks of age and is pooled from weeks
2–10 (n 5 33), 11–20 (n 5 37), and 21–32 (n 5 31). There were no signficiant differences between treatment groups.
The detection of significant CD81 and gd T lymphocyte responses to a genotype of BVDV heterologous
to the challenge strain in the current trial may indicate that cross protective epitopes are presented to T lym-
phocytes following BVDV exposure. Vaccination of cattle with modified live vaccine containing BVDV1
was shown to provide partial protection of cattle from BVDV2 challenge (17). It is interesting that the in
vitro T cell subset responses to the BVDV2-890 were more consistent than to the BVDV2-1373 challenge
strain in the current trial. The challenge strain is highly virulent and may have a suppressive effect on anti-
gen specific T cells in vitro compared to BVDV2-890.
The development of T cell memory to pathogens in the absence of an antibody response has been de-
scribed for other viruses in animals with circulating maternal antibody. Calves challenged with bovine her-
pesvirus 1 (BHV-1) while maternal antibody levels were high had T lymphocytes that proliferated and se-
creted IFNg in response to in vitro BHV-1 antigen in the absence of a measurable antibody response (18,27).
Antigen-specific T cell proliferation or cytokine secretion in the absence of an antibody response has also
been described in cattle vaccinated against bovine respiratory syncytial virus (18), neonatal mice vaccinated
against measles (36), pigs vaccinated against pseudorabies (9), and human neonates exposed to various en-
teroviruses (24). Cell-mediated immune responses do not always occur in the face of maternal antibody,
however. Maternal antibody inhibits the proliferative response of T cells to antigen in mice exposed to
malaria (21) and dogs exposed to rabies or Sendai virus (40). In a direct comparison, maternal antibody in
mice was shown to inhibit the generation of a cytotoxic T cell (CTL) response to respiratory syncytial virus,
but not influenza virus (2). The ability of a young animal to generate a memory T cell response to antigen
in the face of maternal antibody apparently varies among pathogens.
The route of inoculation may also affect the ability of an individual to develop a memory T cell response
to a pathogen in the presence of maternal antibody. Pseudorabies virus (PRV) inoculation of pigs with ma-
ternal antibody resulted in a strong T cell proliferative response to in vitro PRV when an intranasal inocu-
lation protocol was used (9). The T cell response was absent when an intramuscular (i.m.) inoculation pro-
tocol was followed in the same study. Calves with high passive antibody titers to BHV-1 demonstrated a
lymphoproliferative response to antigen following intramuscular (i.m.) vaccination and had a significant
IFNg secretion response following intranasal inoculation. The current study examined T cell responses fol-
lowing an intranasal inoculation with virulent BVDV. An intranasal inoculation best simulates the natural
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FIG. 5. Production of IFNg by peripheral blood mononuclear cells following 5 day in vitro exposure to BVDV-
890 from calves fed colostrum and not challenged with BVDV (group B) and calves fed colostrum and challenged with
BVDV2-1373 at 2–5 weeks of age (group A). Data is presented as weeks after challenge with BVDV at 2–5 weeks of
age and is pooled from weeks 2–10 (n 5 33), 11–20 (n 5 37), and 21–32 (n 5 31). *p , 0.05, **p , 0.01, level of
statistical significance between exposed and nonexposed values (mean6 SEM).
route of infection; however, BVDV vaccines are administered i.m. or subcutaneously (s.c.). Seropositive
calves vaccinated i.m. with a MLV BVDV2 vaccine at 10–14 days of age were not protected from virulent
BVDV2 challenge at 4 months of age (19). In the same study, seronegative calves subjected to the same
vaccination and challenge were protected from clinical signs of disease. The T lymphocyte responses spe-
cific to BVDV were not determined following vaccination. It is unclear if the disparity in results between
the current study and those reported by Ellis and colleagues reflect differences in route of inoculation, dif-
ferences in antigen persistence, or differences in the development of other immune parameters. The results
of the current trial demonstrate that calves can be seronegative for BVDV and stil have immune memory
due to an exposure to the virus during the presence of maternal antibody. This conflicts with the current
practice of identifying BVDV naive and susceptible animals based on the absence of acquired antibody.
Currently, a non-persistently infected calf that is seronegative after maternal antibody has waned is con-
sidered to be immunologically naive to BVDV. The existence of seronegative calves that have T cell mem-
ory to BVDV could significantly impact interpretations of immune responses of calves to BVDV infection
or vaccination.
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